Key Details
Annual ROE
-61.91%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Feb 28, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with MRTX included
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Similar stocks
Sometimes, insider trading goes beyond just trading based on confidential information. It involves manipulating information for profit while also sharing it with others, causing significant impacts on the stock market.
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
Mirati (MRTX) reported earnings 30 days ago. What's next for the stock?
Mirati Therapeutics said on Friday the European medicines regulator's panel has recommended approval of its treatment for a type of lung cancer.
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.
Mirati Therapeutics Inc (NASDAQ:MRTX) stock is dropping today, after news that Bristol-Myers Squibb (BMY) will acquire the company for up to $5.8 billion.
Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing $4.8 billion equity value.
A Bloomberg article suggests that pharma giant Sanofi (SNY) is exploring a potential acquisition deal for small cancer drugmaker Mirati Therapeutics (MRTX).
Mirati (MRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirati (MRTX) reports better-than-expected second-quarter earnings while revenues miss by a slight margin. Its CEO steps down.
FAQ
- What is the ticker symbol for Mirati Therapeutics?
- Does Mirati Therapeutics pay dividends?
- What sector is Mirati Therapeutics in?
- What industry is Mirati Therapeutics in?
- What country is Mirati Therapeutics based in?
- When did Mirati Therapeutics go public?
- Is Mirati Therapeutics in the S&P 500?
- Is Mirati Therapeutics in the NASDAQ 100?
- Is Mirati Therapeutics in the Dow Jones?
- When was Mirati Therapeutics's last earnings report?
- When does Mirati Therapeutics report earnings?
- Should I buy Mirati Therapeutics stock now?